Apellis(APLS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $200 million, and for the full year 2025, it was $1 billion, which included a one-time $275 million upfront payment from the Sobi royalty repurchase agreement [20][21] - Syfovre net product revenue for Q4 was $155 million and $587 million for the full year 2025, with total injections growing approximately 17% year-over-year despite a modest revenue decline due to elevated use of free goods [11][21] - Empaveli reported U.S. net product revenue of $35 million for Q4 and $102 million for the full year 2025, with a market penetration of over 5% after its first full quarter [23][9] Business Line Data and Key Metrics Changes - Syfovre remains a stable revenue stream with strong underlying demand, leading the geographic atrophy market, while Empaveli is positioned as a near-term growth engine with strong early market receptivity [7][12] - Syfovre's total injections grew approximately 17% year-over-year, while Empaveli's launch trajectory reflects strong execution and early market receptivity [11][9] - The company is advancing pivotal trials for Empaveli in focal segmental glomerulosclerosis and delayed graft function, expanding its franchise into new indications [10][19] Market Data and Key Metrics Changes - Empaveli's launch has achieved more than 5% market penetration in the U.S. nephrology market, significantly outpacing other rare nephrology launches [9][12] - Payer coverage for Empaveli is favorable, with 95% of published policies reimbursing to label or with minimal restrictions, supporting strong demand [13][14] - Syfovre continues to lead the geographic atrophy market, supported by extensive clinical and real-world evidence [11][12] Company Strategy and Development Direction - The company focuses on three strategic pillars: strengthening Syfovre's leadership in geographic atrophy, driving growth with Empaveli across rare kidney diseases, and advancing an innovative pipeline [7][10] - The company aims to enhance Syfovre's efficacy and patient experience through next-generation strategies, including a combination with APL-3007 and the development of a prefilled syringe [10][18] - The company is committed to disciplined execution and long-term value creation, supported by a strong balance sheet [5][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Empaveli's trajectory towards blockbuster status, with expectations of continued growth in 2026 [16][26] - The company anticipates a modest inventory reduction in Q1 2026 alongside typical seasonal dynamics, while maintaining a stable net price for Syfovre [22][24] - Management highlighted the importance of patient access and the resumption of co-pay assistance programs, which are expected to improve treatment access for patients [8][57] Other Important Information - The company ended 2025 with $466 million in cash and cash equivalents, providing substantial flexibility to fund operations [24] - The company is actively evaluating alternatives to address approximately $94 million of convertible debt maturing in September 2026 [25] Q&A Session Summary Question: Empaveli launch and growth potential - Management noted that Empaveli is on a clear path to blockbuster status, with a focus on broadening accounts and improving patient identification [29][30] Question: Syfovre's five-year GALE data - Management emphasized the significant benefits of Syfovre, including delaying progression of geographic atrophy by approximately 1.5 years [34][36] Question: Empaveli penetration timeline - Management expects a steady ramp in patient onboarding, with a focus on pediatric and post-transplant patients [39][40] Question: Prefilled syringe impact - Management indicated that the prefilled syringe will enhance practice efficiency and support renewed growth for Syfovre [50][52] Question: Free goods dynamics - Management highlighted the commitment to support patients unable to afford treatment, emphasizing the importance of patient access [97][98] Question: Enrollment expectations for new trials - Management expressed excitement about the upcoming phase 3 trials for Empaveli, noting strong interest from the nephrology community [59][60]